Thank you to our speakers, sponsors, and delegates who joined us in April for the summit!
If you are interested in the 2024 event, please get in touch at info@hansonwade.com
Advancing Biomarker Discovery, Companion Diagnostics & IVD from Research to Commercialisation to Deliver Regulatory Compliant Diagnostic Tests for Patients in Oncology, Immunology & Beyond
April 23 - 25, 2024 | London, UK
Welcome to the 14th Clinical Biomarkers & CDx Europe
After 2 years of a maturing regulatory landscape for companion diagnostics and IVD in Europe, the emergence of new technologies including AI/ML, next generation sequencing and genetic-based diagnostics, coupled with a plethora of groundbreaking collaborations and CE-mark approvals, has led to an inflection point in which personalised medicines for all patients is now on the horizon in Europe.
As such the 14th Clinical Biomarkers & Companion Diagnostics Summit Europe returned as the leading forum for drug developers, diagnostics providers, and regulatory professionals to accelerate the development of drug-diagnostics in diseases with unmet medical needs. With a revamped track design, 2024 had 2 streams dedicated to Biomarker Discovery & Development and Drug-Dx Development & Commercialisation to propel your development.
180+ senior executives across Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics came together and worked on modalities such as gene therapy & protein degradation, and novel biomarkers such as cfDNA & circulating histones amongst many others, for an all-encompassing thought leadership meeting where attendees walked away with actionable insights and meaningful connections to successfully co-develop a European regulatory compliant CDx based precision medicine drug to improve patient outcomes.
What Attendees Learned:
Unearth how field-leading experts are navigating new European regulatory guidelines to enable the harmonious development of drugs and companion diagnostics to improve patient access to personalised medicines
Supercharge your biomarker discovery progress using advances in AI & machine learning to fully harness ‘big data’ across a plethora of disease indications
Leverage Biopharma experience to effectively and compliantly co-develop diagnostics alongside medicines in oncology, CNS, immunology, rare disease and beyond
Maximize patient access to diagnostics with detailed analysis of market access and reimbursement trends across European health authorities
A Snapshot of Our 2024 Expert Speaker Faculty
Fatima Bennai-Sanfourche
Senior Director - QA & RA Compliance, Medical Devices, Combination Products & eHealth
Bayer
Stephanie Traub
Associate Director, Bioanalytical Scientific Manager, Translational Biomarkers & Bioanalysis
UCB S.A.
Hear What Previous Attendees have Said:
"Knowledgeable presenters and optionality to move between the 2 workstreams. Attendees were also very generous in providing insights!"
VP Global Regulatory Sciences, Bristol Myers Squibb
"The Clinical Biomarkers & CDx Summit Europe brought a good mix of established vendors and new vendors offering more cutting-edge technologies. Very interesting technical presentation!"
Associate Director, Seagen
"Excellent networking opportunities thanks to sufficient Breaks. Good presentations on a sensitive topic that concerns the whole community. Great speakers!”
Translational Medicine Scientist, Debiopharm